Krystal Biotech Reports Strong 2025 Financials, $955M in Cash Reserves, and Expansion Plans for Rare Disease Therapies.
ByAinvest
Monday, Jan 12, 2026 12:17 am ET1min read
KRYS--
Krystal Biotech reported preliminary unaudited financial results for 2025, with VYJUVEK revenue expected to reach $388-389 million and cash reserves at $955 million. The company is advancing a pipeline of rare disease therapies and plans to have at least four marketed medicines by 2030, while maintaining profitability and investing in broader programs. For 2026, Krystal anticipates combined non-GAAP R&D and SG&A expenses between $175 million and $195 million.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet